RED HOT Contributors


TCT 2017: Abbott’s Xience coronary stent helps patients feel better faster than open-heart surgery


Abbott logoAbbott (NYSE:ABT) reported today that patients who were treated with the company’s Xience coronary stent for left-main coronary artery disease felt better faster compared to patients who had open-heart surgery.

The data were presented at this year’s Transcatheter Cardiovascular Therapeutics meeting during a late-breaking session.

“For any treatment, it’s important to not only consider clinical outcomes such as recurrent heart attacks or stroke, but also to consider the effect of the treatment on a patient’s quality of life,” study investigator Dr. Suzanne Baron said in prepared remarks.

Get the full story at our sister site, Drug Delivery Business News.


We Support OUR Contributors

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast